AbbVie stock soared over 3% after positive analyst notes on strong Q1 earnings.

From Nasdaq: 2025-04-28 19:02:00

AbbVie’s stock price rose over 3% after bullish analyst notes following strong first-quarter earnings results. BMO Capital reiterated an outperform rating and $215 price target, citing high sales of Skyrizi and Rinvoq. HSBC also named AbbVie a good value stock. However, Motley Fool’s Stock Advisor did not include AbbVie in its list of 10 best stocks to buy now, which have historically produced high returns. AbbVie’s positive momentum and potential for growth make it an attractive investment option despite not being on Stock Advisor’s list.



Read more at Nasdaq: Why AbbVie Stock Trounced the Market Today